Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. - Wikidata - wikimedia - TriplyDB

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.

http://www.wikidata.org/entity/Q37559470

about

At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study.

P2860

Q43920667-4BE3DB78-E9C7-4D2C-A285-1F466E8BD51A

P2860

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.

http://www.wikidata.org/entity/Q37559470

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy of deferred dosing of ...... antation for multiple myeloma.

@en

Efficacy of deferred dosing of ...... antation for multiple myeloma.

@nl

type

label

Efficacy of deferred dosing of ...... antation for multiple myeloma.

@en

Efficacy of deferred dosing of ...... antation for multiple myeloma.

@nl

prefLabel

Efficacy of deferred dosing of ...... antation for multiple myeloma.

@en

Efficacy of deferred dosing of ...... antation for multiple myeloma.

@nl

P1433

Q37559470-6737B8E6-3395-42A2-B47D-2A1863FE327F

P1476

Q37559470-AE6C62D7-AA74-467B-98FC-6490008DE4B2

P2093

Q37559470-52794B51-B96D-49D7-A519-90CE43C15AA9

Q37559470-532A7C94-DFEC-41F5-BDAB-9AE6B6162BCA

Q37559470-5767B0B1-A544-41FC-A254-E8F24F335A94

Q37559470-5F7CB1CC-4C05-4EE9-9C2D-41A3E5F9C417

Q37559470-602EE6FC-B75F-475A-A9FA-1A94BFAC5780

Q37559470-A0A18BB4-0FD5-4055-AE75-AA62E1074673

Q37559470-A7F37D5E-50CF-4F1F-8A03-8E888D0591E9

Q37559470-E90E834D-22D0-45A6-A69F-A90FD92AF308

Q37559470-FCA50C77-B692-47C1-9080-B904F9913D0F

P2860

Q37559470-23B0AEAB-0242-4EC3-8583-312DCF8BA4B2

Q37559470-258FCF01-47BE-457E-A3BD-0977748B847B

Q37559470-25908FB5-BAD6-46B7-ABAB-5148E6C55EB0

Q37559470-281A3D7D-5AA6-4CEE-87E2-627A5E86CB7D

Q37559470-338094C0-7A94-4542-9ED7-A18885AFE1FE

Q37559470-36E973ED-558E-4437-8ADA-A733D8E7E91B

Q37559470-37C1D5B5-D85F-4122-B6D0-3A6F0E209617

Q37559470-3DE3AB3C-2611-483D-B49F-7A0E72F158A1

Q37559470-5707593A-639C-4DD0-8F86-5AEF63DFB9A8

Q37559470-600402DE-9024-4AFA-9BC5-D19703E28BF3

P2888

Q37559470-01D70F2C-442D-48CC-BF9A-37E17E01D6E3

P304

Q37559470-CC0D7F0F-3209-43AB-ACF6-44AC196AC236

P31

Q37559470-B238DD7F-C0C8-4017-A604-142B0848C77E

P356

Q37559470-E3C95F98-3E49-4DCF-95A8-57838F4F55B1

P407

Q37559470-800C4062-D1B2-4146-A321-9D7341EF6293

P433

Q37559470-156C6247-7E93-4801-879C-AF1384019401

P478

Q37559470-D2351E77-90AC-45EC-A146-0B5087603572

P50

Q37559470-F9226481-FC51-4C69-9495-FB0A9B5534A7

P577

Q37559470-22D7929A-A8E2-4DE4-9894-B9107E608545

P5875

Q37559470-D2697AE6-359E-4C35-AB6F-7E8071DC11E3

P698

Q37559470-97FCE207-9CEA-47DA-8FF1-5A627A53DA43

P932

Q37559470-C4282B16-3BEE-4296-8375-EAC2476ED435

P356

P1433

Bone Marrow Transplantation

P1476

Efficacy of deferred dosing of ...... lantation for multiple myeloma

@en

P2093

G Carrum

http://www.w3.org/2001/XMLSchema#string

H E Heslop

http://www.w3.org/2001/XMLSchema#string

H Liu

http://www.w3.org/2001/XMLSchema#string

J E Cox

http://www.w3.org/2001/XMLSchema#string

J Wu

http://www.w3.org/2001/XMLSchema#string

M K Brenner

http://www.w3.org/2001/XMLSchema#string

R May

http://www.w3.org/2001/XMLSchema#string

R T Kamble

http://www.w3.org/2001/XMLSchema#string

S Campos

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.

Hematopoietic growth factors: ESMO recommendations for the applications.

Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.

Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support.

Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.

Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.

Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.

Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit.

P2888

P304

219-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2013.149

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257463616

http://www.w3.org/2001/XMLSchema#string

P698

24096822

http://www.w3.org/2001/XMLSchema#string

P932

3915247

http://www.w3.org/2001/XMLSchema#string